ABSTRACT
Viral hepatitis represents a major danger to public health, and is a globally leading cause of death. The five liver-specific viruses: Hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, and hepatitis E virus, each have their own unique epidemiology, structural biology, transmission, endemic patterns, risk of liver complications, and response to antiviral therapies. There remain few options for treatment, in spite of the increasing prevalence of viral-hepatitis-caused liver disease. Furthermore, chronic viral hepatitis is a leading worldwide cause of both liver-related morbidity and mortality, even though effective treatments are available that could reduce or prevent most patients' complications. In 2016, the World Health Organization released its plan to eliminate viral hepatitis as a public health threat by the year 2030, along with a discussion of current gaps and prospects for both regional and global eradication of viral hepatitis. Today, treatment is sufficiently able to prevent the disease from reaching advanced phases. However, future therapies must be extremely safe, and should ideally limit the period of treatment necessary. A better understanding of pathogenesis will prove beneficial in the development of potential treatment strategies targeting infections by viral hepatitis. This review aims to summarize the current state of knowledge on each type of viral hepatitis, together with major innovations.
Subject(s)
Antiviral Agents , Hepatitis, Viral, Human , Humans , Antiviral Agents/therapeutic use , Hepatitis, Viral, Human/epidemiology , Hepatitis, Viral, Human/virology , Hepatitis, Viral, Human/therapy , Hepatitis, Viral, Human/diagnosis , Hepatitis Viruses/pathogenicity , Hepatitis Viruses/drug effects , Hepatitis Viruses/genetics , Prevalence , Liver/virology , Liver/pathologyABSTRACT
Metagenomic next-generation sequencing (mNGS) has enabled the high-throughput multiplexed identification of sequences from microbes of potential medical relevance. This approach has become indispensable for viral pathogen discovery and broad-based surveillance of emerging or re-emerging pathogens. From 2015 to 2019, plasma was collected from 9586 individuals in Cameroon and the Democratic Republic of the Congo enrolled in a combined hepatitis virus and retrovirus surveillance program. A subset (n = 726) of the patient specimens was analyzed by mNGS to identify viral co-infections. While co-infections from known blood-borne viruses were detected, divergent sequences from nine poorly characterized or previously uncharacterized viruses were also identified in two individuals. These were assigned to the following groups by genomic and phylogenetic analyses: densovirus, nodavirus, jingmenvirus, bastrovirus, dicistrovirus, picornavirus, and cyclovirus. Although of unclear pathogenicity, these viruses were found circulating at high enough concentrations in plasma for genomes to be assembled and were most closely related to those previously associated with bird or bat excrement. Phylogenetic analyses and in silico host predictions suggested that these are invertebrate viruses likely transmitted through feces containing consumed insects or through contaminated shellfish. This study highlights the power of metagenomics and in silico host prediction in characterizing novel viral infections in susceptible individuals, including those who are immunocompromised from hepatitis viruses and retroviruses, or potentially exposed to zoonotic viruses from animal reservoir species.
Subject(s)
Chiroptera , Coinfection , Virus Diseases , Viruses , Animals , Satellite Viruses/genetics , Metagenomics , Phylogeny , Viruses/genetics , Retroviridae/genetics , Hepatitis Viruses/genetics , Insecta/genetics , High-Throughput Nucleotide SequencingABSTRACT
Commonly misused substances such as alcohol, cocaine, heroin, methamphetamine, and opioids suppress immune responses and may impact viral pathogenesis. In recent years, illicit use of opioids has fueled outbreaks of several viral pathogens, including the human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). This review focuses on the myriad of mechanisms by which drugs of abuse impact viral replication and disease progression. Virus-drug interactions can accelerate viral disease progression and lead to increased risk of virus transmission.
Subject(s)
HIV Infections/virology , HIV/drug effects , Hepatitis Viruses/drug effects , Hepatitis/virology , Illicit Drugs/adverse effects , Substance-Related Disorders/virology , Animals , HIV/genetics , HIV/pathogenicity , HIV/physiology , HIV Infections/immunology , Hepatitis/immunology , Hepatitis Viruses/genetics , Hepatitis Viruses/pathogenicity , Hepatitis Viruses/physiology , Humans , Substance-Related Disorders/immunologyABSTRACT
In 2016 the World Health Organization set the goal of eliminating hepatitis B globally by 2030. Horizontal transmission has been greatly reduced in most countries by scaling up coverage of the infant HBV vaccine series, and vertical transmission is therefore becoming increasingly dominant. Here we show that scaling up timely hepatitis B birth dose vaccination to 90% of new-borns in 110 low- and middle-income countries by 2030 could prevent 710,000 (580,000 to 890,000) deaths in the 2020 to 2030 birth cohorts compared to status quo, with the greatest benefits in Africa. Maintaining this could lead to elimination by 2030 in the Americas, but not before 2059 in Africa. Drops in coverage due to disruptions in 2020 may lead to 15,000 additional deaths, mostly in South-East Asia and the Western Pacific. Delays in planned scale-up could lead to an additional 580,000 deaths globally in the 2020 to 2030 birth cohorts.
Subject(s)
Hepatitis B Vaccines/administration & dosage , Hepatitis B/prevention & control , Africa/epidemiology , Americas/epidemiology , Asia, Southeastern/epidemiology , Birth Cohort , Disease Eradication/statistics & numerical data , Female , Hepatitis B/epidemiology , Hepatitis B/mortality , Hepatitis B/virology , Hepatitis Viruses/genetics , Hepatitis Viruses/immunology , Humans , Infant , Infant, Newborn , Male , Vaccination , World Health OrganizationABSTRACT
In this special issue, we present collected updated data on the hepatitis viruses [...].
Subject(s)
Hepatitis Viruses/genetics , Hepatitis, Viral, Human/virology , Animals , Hepatitis Viruses/chemistry , Hepatitis Viruses/classification , Humans , Viral Proteins/chemistry , Viral Proteins/genetics , Viral Proteins/metabolism , Virus Diseases/virology , Viruses/classification , Viruses/geneticsABSTRACT
There is strong evidence that equine parvovirus-hepatitis (EqPV-H) is associated with the onset of Theiler's disease, an acute hepatic necrosis, in horses. However, the impact of this virus on other hepatopathies remains unknown. The objective of this retrospective study was to evaluate the prevalence and quantify the viral loads of EqPV-H in formalin-fixed, paraffin-embedded equine and donkey livers with various histopathologic abnormalities. The pathologies included cirrhosis, circulatory disorders of the liver, toxic and metabolic hepatic diseases as well as neoplastic and inflammatory diseases (n = 84). Eight normal liver samples were included for comparison as controls. EqPV-H DNA was qualitatively and quantitatively measured by real-time PCR and digital PCR, respectively. The virus was detected in two livers originating from horses diagnosed with abdominal neoplasia and liver metastasis (loads of 5 × 103 and 9.5 × 103 genome equivalents per million cells). The amount of viral nucleic acids measured indicates chronic infection or persistence of EqPV-H, which might have been facilitated by the neoplastic disease. In summary, this study did not provide evidence for EqPV-H being involved in hepatopathies other than Theiler's disease.
Subject(s)
Hepatitis Viruses/genetics , Hepatitis, Viral, Animal/diagnosis , Liver Diseases/diagnosis , Liver Diseases/veterinary , Liver/pathology , Mass Screening/veterinary , Parvoviridae Infections/diagnosis , Parvovirus/genetics , Animals , Equidae/virology , Female , Hepatitis, Viral, Animal/epidemiology , Horse Diseases/diagnosis , Horse Diseases/virology , Horses/virology , Liver/virology , Liver Diseases/epidemiology , Liver Diseases/virology , Male , Parvoviridae Infections/epidemiology , Parvovirus/isolation & purification , Persistent Infection/diagnosis , Persistent Infection/virology , Real-Time Polymerase Chain Reaction , Retrospective Studies , Serologic Tests , Viral LoadABSTRACT
Defining genetic diversity of viral infections directly from patient specimens is the ultimate goal of surveillance. Simple tools that can provide full-length sequence information on blood borne viral hepatitis viruses: hepatitis C, hepatitis B and hepatitis D viruses (HCV, HBV and HDV) remain elusive. Here, an unbiased metagenomic next generation sequencing approach (mNGS) was used for molecular characterization of HCV infections (n = 99) from Israel which yielded full-length HCV sequences in 89% of samples, with 7 partial sequences sufficient for classification. HCV genotypes were primarily 1b (68%) and 1a (19%), with minor representation of genotypes 2c (1%) and 3a (8%). HBV/HDV coinfections were characterized by suppressed HBV viral loads, resulting in sparse mNGS coverage. A probe-based enrichment approach (xGen) aiming to increase HBV and HDV coverage was validated on a panel of diverse genotypes, geography and titers. The method extended HBV genome coverage a median 61% (range 8-84%) and provided orders of magnitude boosts in reads and sequence depth for both viruses. When HBV-xGen was applied to Israeli samples, coverage was improved by 28-73% in 4 samples and identified HBV genotype A1, A2, D1 specimens and a dual B/D infection. Abundant HDV reads in mNGS libraries yielded 18/26 (69%) full genomes and 8 partial sequences, with HDV-xGen only providing minimal extension (3-11%) of what were all genotype 1 genomes. Advanced molecular approaches coupled to virus-specific capture probes promise to enhance surveillance of viral infections and aid in monitoring the spread of local subtypes.
Subject(s)
Blood/virology , Hepatitis Viruses/genetics , High-Throughput Nucleotide Sequencing , Metagenomics , Cohort Studies , Genotype , Hepatitis Viruses/isolation & purification , HumansABSTRACT
BACKGROUND: A serum alanine aminotransferase (ALT) test is currently demanded for blood donation in China. One of the major reasons to include such a test is possible etiology of known or unknown hepatotropic viruses. However, this hypothesis has never been examined convincingly. STUDY DESIGN AND METHODS: The study recruited 90 Chinese blood donors that were divided into three groups based on their ALT values. Serum virome from these donors was explored using a metagenomics approach with enhanced sensitivity resolved at single sequencing reads. RESULTS: Anellovirus and pegivirus C (GBV-C) were detected among these donors. None of them were found solely in donors with abnormal liver enzyme. Anellovirus was highly prevalent (93.3%) and the co-infection with multiple genera (alpha, beta, and gammatorquevirus) were more common in the donors with normal ALT values in comparison to those with elevated ALT (single/double/triple Anellovirus genera, 1/3/24 vs. 7/7/14 or 6/7/13, p = 0.009). For unmapped reads that accounted for 15 ± 14.9% of the data, similarity-based (BLASTN, BLASTP, and HMMER3) and similarity-independent (k-mer frequency) analysis identified several circular rep encoding ssDNA (CRESS-DNA) genomes. Direct PCR testing indicated these genomes were likely reagent contaminants. CONCLUSION: Viral etiology is not responsible for elevated ALT levels in Chinese blood donors. The ALT test, if not abandoned, should be adjusted for its cutoff in response to donor shortage in China.
Subject(s)
Alanine Transaminase/blood , Anelloviridae , Blood Donors , Genome, Viral , Hepatitis Viruses , Hepatitis, Viral, Human , Adult , Anelloviridae/genetics , Anelloviridae/metabolism , Asian People , China/epidemiology , Female , Hepatitis Viruses/genetics , Hepatitis Viruses/metabolism , Hepatitis, Viral, Human/blood , Hepatitis, Viral, Human/epidemiology , Hepatitis, Viral, Human/genetics , Humans , Male , Middle Aged , PrevalenceABSTRACT
The United States Preventive Services Task Force recommends hepatitis C testing people born from 1945 to 1965, "birth cohort" as well as hepatitis C and hepatitis B testing people from countries of birth with endemic infection risk. We automated the hospital electronic health record system to test birth cohort and those born in countries with endemic infection risk. A script is launched searching the laboratory database upon registration for any hepatitis C antibody, hepatitis C RNA and/or hepatitis B surface antigen result. If no positive result was found, a hepatitis C antibody/reflex RNA and/or hepatitis B surface antigen were ordered. A patient navigator received weekly results and assisted patients with positive serology to schedule an appointment with their primary care provider or treatment specialist. A total of 10 726 participants were hepatitis C antibody tested, with 6.9% antibody positive. Monthly hepatitis C testing from January to July 2016 compared to August 2016-August 2017 increased 342% as a result of "birth cohort" testing. Following country of birth testing, monthly hepatitis B and hepatitis C testing increased 91%, and 44%, respectively, during June-August 2017 compared to September 2017-March 2018. 67% of hepatitis C-positive patients were linked to care. If the navigator contacted the patient, 92% were linked to care, and 32% were treated. Of hepatitis B surface antigen-positive patients, 43% were linked to care, 5% were on treatment, and 15% started treatment. Automated electronic health record ordering of hepatitis C and/or hepatitis B testing is feasible and increases testing. In the population tested, much improvement is needed with linkage to care and treatment.
Subject(s)
Electronic Health Records , Hepatitis, Viral, Human/epidemiology , Age Factors , Diagnostic Tests, Routine , Hepatitis Viruses/classification , Hepatitis Viruses/genetics , Hepatitis Viruses/immunology , Hepatitis, Viral, Human/diagnosis , Humans , Serologic TestsABSTRACT
OBJECTIVES: In the United States, the Acute Liver Failure Study Group (ALFSG) registry lists approximately 11% of cases as of indeterminate etiology (IND-ALF) as determined by the respective local site principal investigator (PI). Traditionally, IND-ALF has prompted concern that other viruses or toxins might be implicated. We hypothesized that many IND- ALF cases would have an identifiable etiology upon further investigation. Improving the identification process should reduce the number of truly indeterminate cases. METHODS: Specific definitions for each etiology ("etiology-specific algorithms") were developed by a Causality Adjudication Committee that included six reviewers (each with 20 or more years of experience). Of 2718 patients with ALF, 303 initially deemed IND-ALF by site PIs underwent committee review guided by the algorithms. Acetaminophen (APAP) protein adducts were measured in sera when available, additional HEV testing was performed, and viral sequences sought by microarray analysis and metagenomic next-generation sequencing (mNGS). Study sites were asked to provide liver biopsy and/or explant reports and to update serological findings not reported previously. RESULTS: Nearly half (142, 46.9%) of the 303 IND-ALF cases could be reassigned to a single, defined etiology and rated as highly likely or probable; 11 additional cases, upon review, did not meet ALF criteria. Amongst reassigned etiologies, 45 were previously unrecognized APAP, 34 autoimmune hepatitis (AIH), 24 drug-induced liver injury (DILI), 13 various viral causes, 12 ischemia, and 14 miscellaneous other etiologies. The remaining 150, deemed true IND-ALF, represented just 5.5%. CONCLUSIONS: The indeterminate etiology in ALF includes patients with a diagnosis that is discernible after closer examination. Revision of etiologic diagnoses of indeterminate cases using added testing and expert opinion is useful in understanding all aspects of ALF.
Subject(s)
Chemical and Drug Induced Liver Injury/diagnosis , Hepatitis, Autoimmune/diagnosis , Hepatitis, Viral, Human/diagnosis , Liver Failure, Acute/etiology , Acetaminophen/adverse effects , Adolescent , Adult , Aged , Aged, 80 and over , Algorithms , Chemical and Drug Induced Liver Injury/blood , Chemical and Drug Induced Liver Injury/complications , DNA, Viral/isolation & purification , Female , Hepatitis Viruses/genetics , Hepatitis Viruses/isolation & purification , Hepatitis, Autoimmune/blood , Hepatitis, Autoimmune/complications , Hepatitis, Viral, Human/complications , Hepatitis, Viral, Human/virology , High-Throughput Nucleotide Sequencing/methods , Humans , Liver Failure, Acute/blood , Liver Failure, Acute/epidemiology , Male , Metagenomics/methods , Middle Aged , RNA, Viral/isolation & purification , Registries/statistics & numerical data , United States/epidemiology , Young AdultABSTRACT
Real-time PCR assays for nucleic acid testing (NAT) of hepatitis viruses A-E and for HIV-1 and HIV-2 have been developed; however, a multiplex assay that can simultaneously detect all of these agents is not yet available. Standardized TaqMan assays for detection of hepatitis viruses A-E have been described and applied to TaqMan Array Cards (TAC) which are capable of multiple pathogen detection using a single set of optimized PCR conditions. Assays for three gene regions of HIV-1 (long-terminal repeat (LTR), gag, and polymerase) and HIV-2 (overlap of LTR and gag, protease and integrase) were designed using the hepatitis assay conditions. Nucleic acid extracts of HIV-1-infected samples (44 plasma, 41 whole blood, 20 HIV-1 viral stocks) were tested on the TAC cards; 98 were reactive (92%) with 70 in multiple gene regions. Twenty-four of the 27 (89%) HIV-2 specimens (10 plasma, 1 PBMC lysate, 6 whole blood and 10 plasmids containing HIV-2 polymerase) were detected on TAC. No HIV or hepatitis virus sequences were detected in 30 HIV-negative samples (specificity 100%). Three HBV and 18 HCV co-infections were identified in the HIV-1-infected specimens. Multi-pathogen detection using TAC could provide a rapid, sensitive and more efficient method of surveying for a variety of infectious disease nucleic acids.
Subject(s)
HIV Infections/diagnosis , HIV-1/isolation & purification , HIV-2/isolation & purification , Hepatitis Viruses/isolation & purification , Hepatitis, Viral, Human/diagnosis , Microarray Analysis/methods , Real-Time Polymerase Chain Reaction/methods , HIV Infections/virology , HIV-1/genetics , HIV-2/genetics , Hepatitis Viruses/genetics , Hepatitis, Viral, Human/virology , Sensitivity and Specificity , Time FactorsABSTRACT
Rodents and bats are now widely recognised as important sources of zoonotic virus infections in other mammals, including humans. Numerous surveys have expanded our knowledge of diverse viruses in a range of rodent and bat species, including their origins, evolution, and range of hosts. In this study of pegivirus and human hepatitis-related viruses, liver and serum samples from Vietnamese rodents and bats were examined by PCR and sequencing. Nucleic acids homologous to human hepatitis B, C, E viruses were detected in liver samples of 2 (1.3%) of 157 bats, 38 (8.1%), and 14 (3%) of 470 rodents, respectively. Hepacivirus-like viruses were frequently detected (42.7%) in the bamboo rat, Rhizomys pruinosus, while pegivirus RNA was only evident in 2 (0.3%) of 638 rodent serum samples. Complete or near-complete genome sequences of HBV, HEV and pegivirus homologues closely resembled those previously reported from rodents and bats. However, complete coding region sequences of the rodent hepacivirus-like viruses substantially diverged from all of the currently classified variants and potentially represent a new species in the Hepacivirus genus. Of the viruses identified, their routes of transmission and potential to establish zoonoses remain to be determined.
Subject(s)
Chiroptera/virology , Hepatitis Viruses , Hepatitis, Viral, Animal/epidemiology , Hepatitis, Viral, Animal/virology , Hepatitis, Viral, Human/epidemiology , Hepatitis, Viral, Human/virology , Rodentia/virology , Animals , Genome, Viral , Hepatitis Viruses/classification , Hepatitis Viruses/genetics , Hepatitis, Viral, Animal/diagnosis , Hepatitis, Viral, Human/diagnosis , Humans , Phylogeny , Public Health Surveillance , RNA, Viral , Vietnam/epidemiology , Zoonoses/epidemiology , Zoonoses/virologyABSTRACT
Using a metagenomic approach, we identified hepatitis A virus among cases of acute febrile illnesses that occurred in 2008-2012 in Brazil suspected as yellow fever. These findings reinforce the challenge facing routine clinical diagnosis in complex epidemiological scenarios.
Subject(s)
Humans , Yellow Fever/diagnosis , Hepatitis A/diagnosis , Yellow Fever/epidemiology , Yellow fever virus/genetics , Brazil/epidemiology , Metagenomics , Genotype , Hepatitis A/epidemiology , Hepatitis Viruses/geneticsABSTRACT
BACKGROUND: Twelve percent of all acute liver failure (ALF) cases are of unknown origin, often termed indeterminate. A previously unrecognized hepatotropic virus has been suspected as a potential etiologic agent. METHODS: We compared the performance of metagenomic next-generation sequencing (mNGS) with confirmatory nucleic acid testing (NAT) to routine clinical diagnostic testing in detection of known or novel viruses associated with ALF. Serum samples from 204 adult ALF patients collected from 1998 to 2010 as part of a nationwide registry were analyzed. One hundred eighty-seven patients (92%) were classified as indeterminate, while the remaining 17 patients (8%) served as controls, with infections by either hepatitis A virus or hepatitis B virus (HBV), or a noninfectious cause for their ALF. RESULTS: Eight cases of infection from previously unrecognized viral pathogens were detected by mNGS (4 cases of herpes simplex virus type 1, including 1 case of coinfection with HBV, and 1 case each of HBV, parvovirus B19, cytomegalovirus, and human herpesvirus 7). Several missed dual or triple infections were also identified, and assembled viral genomes provided additional information on genotyping and drug resistance mutations. Importantly, no sequences corresponding to novel viruses were detected. CONCLUSIONS: These results suggest that ALF patients should be screened for the presence of uncommon viruses and coinfections, and that most cases of indeterminate ALF in the United States do not appear to be caused by novel viral pathogens. In the future, mNGS testing may be useful for comprehensive diagnosis of viruses associated with ALF, or to exclude infectious etiologies.
Subject(s)
Genome, Viral/genetics , Hepatitis Viruses/genetics , High-Throughput Nucleotide Sequencing/methods , Liver Failure, Acute/virology , Metagenomics/methods , Adolescent , Adult , DNA, Viral/genetics , Female , Hepatitis, Viral, Human/diagnosis , Hepatitis, Viral, Human/genetics , Humans , Male , Middle Aged , RNA, Viral/genetics , Retrospective Studies , Young AdultABSTRACT
KIs virus (KIs-V) is a putative new hepatitis virus recently identified from Japan. Prevalence of this virus was found to be significantly higher in individuals with past exposure to hepatitis E virus and having moderately raised alanine aminotransferase levels. The present work was undertaken to see the circulation of this virus in India. Blood samples (n=648) collected during hepatitis E outbreaks from different states (1990-2014) were screened by PCR. One anti- HEV IgM positive serum was found to be positive for two closely related viruses, one with 100% and other with 94.4% homology with the KIs-V sequence reported from Japan. This is the first evidence of KIs-V occurrence in India. Significance of association between KIs-V and hepatitis E virus still remains unanswered. Further studies are needed for understanding pathogenesis of KIs-V in humans.
Subject(s)
Hepatitis Viruses/isolation & purification , Adolescent , Adult , Aged , Aged, 80 and over , Blood/virology , Child , Child, Preschool , Hepatitis Viruses/classification , Hepatitis Viruses/genetics , Humans , India , Infant , Middle Aged , Phylogeny , Polymerase Chain Reaction , Sequence Homology , Young AdultABSTRACT
BACKGROUND: Migration because of miscellaneous political crises in countries in the Middle East and Africa is a global challenge for whole Europe from an economic, social, and public health view. There is an urgent need to generate comprehensive, evidence-based data to expedite further screening and vaccination strategies. METHODS: A total of 604 individuals ranging in age from 2 to 68 years who enrolled at a single reception center were tested for the prevalence of serologic markers for hepatitis virus types A, B, C, D, and E (HAV, HBV, HCV, HDV, HEV), respectively. RESULTS: Anti-HAV antibody prevalence was 91.2 and 70.3% in children younger than 18 years of age. The prevalence of anti-HEV antibodies was 20.1% among the individuals. 3.0% were positive for hepatitis B surface antigen, whereas 15.2% tested positive for anti-hepatitis B core antigen. None of the refugees tested positive for anti-HDV. 14.1% of refugees were vaccinated against hepatitis B and had a protective anti-hepatitis B surface level of at least 10 mIU/ml. Significant differences in vaccination status were found between the regions (Eastern Mediterranean Region with 77/482 (16.0%; 95% confidence interval=12.7-19.3%) versus African Region with 1/55 (1.8%; 95% confidence interval=0-5.0%). The prevalence of anti-HCV antibodies was 1.2% (n=7), with 0.7% HCV RNA positivity; 16.7% of hepatitis B surface antigen-positive individuals were HCV coinfected (n=3). CONCLUSION: The prevalence of refugees with previous exposure to hepatitis viruses was higher than that in the general German population, but lower than in other migrant populations in Germany. The vaccination status against hepatitis B was poor.
Subject(s)
Emigrants and Immigrants , Emigration and Immigration , Hepatitis Antibodies/blood , Hepatitis Viruses/immunology , Hepatitis, Viral, Human/blood , Hepatitis, Viral, Human/epidemiology , Refugees , Adolescent , Adult , Aged , Biomarkers/blood , Child , Child, Preschool , Female , Germany/epidemiology , Hepatitis B Surface Antigens/blood , Hepatitis Viruses/genetics , Hepatitis, Viral, Human/prevention & control , Hepatitis, Viral, Human/virology , Humans , Infant , Male , Middle Aged , RNA, Viral/genetics , Seroepidemiologic Studies , Vaccination , Viral Hepatitis Vaccines/administration & dosage , Viral Load , Young AdultABSTRACT
Chronic hepatitis B is a persistent and progressive inflammatory liver disease caused by infection with the hepatitis B virus (HBV). More than 240 million individuals are infected with HBV worldwide and hepatitis B accounts for an estimated 650 000 deaths annually. Approximately up to 30% of chronically infected patients will develop complications of HBV infection including, but not limited to, liver cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Currently approved therapies have improved clinical outcomes, but have a considerable side-effect profile, elevated cost, and a finite course of treatment. This has led to a growing interest in research for new therapies. As the mechanisms for HBV replication are becoming better understood, new potential targets have been discovered, leading to the development of new therapies. In this article, we describe the promising therapies that are under evaluation, showing their mechanisms of action, effects, and stage of development.
Subject(s)
Antiviral Agents/therapeutic use , Drug Discovery , Hepatitis B, Chronic/drug therapy , Hepatitis Viruses/drug effects , Virus Replication/drug effects , Antiviral Agents/adverse effects , Drug Resistance, Viral , Genotype , Hepatitis B, Chronic/diagnosis , Hepatitis B, Chronic/virology , Hepatitis Viruses/genetics , Hepatitis Viruses/growth & development , Humans , Treatment OutcomeSubject(s)
Carcinoma, Hepatocellular/genetics , Fatty Liver , Hepatitis, Viral, Human , Liver Neoplasms/genetics , Liver Transplantation/methods , Liver , Animals , DEAD-box RNA Helicases/genetics , Fatty Liver/genetics , Fatty Liver/therapy , Hepatitis Viruses/classification , Hepatitis Viruses/genetics , Hepatitis Viruses/pathogenicity , Hepatitis, Viral, Human/immunology , Hepatitis, Viral, Human/therapy , Hepatitis, Viral, Human/virology , Humans , Liver/immunology , Liver/metabolism , Liver/pathology , Mice , MicroRNAs/pharmacology , Molecular Targeted Therapy/methods , Ribonuclease III/geneticsABSTRACT
The hepatitis viruses represent a major public health problem worldwide. Procedures for characterization of the genomic composition of their populations, accurate diagnosis, identification of multiple infections, and information on inhibitor-escape mutants for treatment decisions are needed. Deep sequencing methodologies are extremely useful for these viruses since they replicate as complex and dynamic quasispecies swarms whose complexity and mutant composition are biologically relevant traits. Population complexity is a major challenge for disease prevention and control, but also an opportunity to distinguish among related but phenotypically distinct variants that might anticipate disease progression and treatment outcome. Detailed characterization of mutant spectra should permit choosing better treatment options, given the increasing number of new antiviral inhibitors available. In the present review we briefly summarize our experience on the use of deep sequencing for the management of hepatitis virus infections, particularly for hepatitis B and C viruses, and outline some possible new applications of deep sequencing for these important human pathogens.
Subject(s)
Genome, Viral , Hepatitis Viruses/genetics , Hepatitis, Viral, Human/virology , High-Throughput Nucleotide Sequencing , Animals , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Disease Management , Drug Resistance, Viral , Genomics/methods , Genotype , Hepacivirus/drug effects , Hepacivirus/genetics , Hepatitis B virus/drug effects , Hepatitis B virus/genetics , Hepatitis Delta Virus/drug effects , Hepatitis Delta Virus/genetics , Hepatitis Viruses/drug effects , Hepatitis, Viral, Human/diagnosis , Hepatitis, Viral, Human/therapy , Humans , Mutation , Treatment Failure , Treatment OutcomeABSTRACT
We applied a newly developed bioinformatics system called VirusScan to investigate the viral basis of 6,813 human tumors and 559 adjacent normal samples across 23 cancer types and identified 505 virus positive samples with distinctive, organ system- and cancer type-specific distributions. We found that herpes viruses (e.g., subtypes HHV4, HHV5, and HHV6) that are highly prevalent across cancers of the digestive tract showed significantly higher abundances in tumor versus adjacent normal samples, supporting their association with these cancers. We also found three HPV16-positive samples in brain lower grade glioma (LGG). Further, recurrent HBV integration at the KMT2B locus is present in three liver tumors, but absent in their matched adjacent normal samples, indicating that viral integration induced host driver genetic alterations are required on top of viral oncogene expression for initiation and progression of liver hepatocellular carcinoma. Notably, viral integrations were found in many genes, including novel recurrent HPV integrations at PTPN13 in cervical cancer. Finally, we observed a set of HHV4 and HBV variants strongly associated with ethnic groups, likely due to viral sequence evolution under environmental influences. These findings provide important new insights into viral roles of tumor initiation and progression and potential new therapeutic targets.